IDIOSYNCRATIC OCULAR SYMPTOMS ASSOCIATED WITH THE ESTRADIOL TRANSDERMAL ESTROGEN REPLACEMENT PATCH SYSTEM

被引：20

作者：

GURWOOD, AS

GURWOOD, I

GUBMAN, DT

BRZEZICKI, LJ

机构：

[1] Eye Institute of the Pennsylvania College of Optometry, Philadelphia, PA

来源：

OPTOMETRY AND VISION SCIENCE | 1995年 / 72卷 / 01期

关键词：

ESTROGEN; ESTRADIOL; CLIMACTERIC PERIOD; HYSTERECTOMY; PREMARIN;

D O I：

10.1097/00006324-199501000-00006

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

The Estradiol Transdermal Estrogen Replacement Patch System (Estraderm) is designed to provide continuous estrogen replacement therapy through a rate-limiting membrane applied to the skin. The relative advantage of the patch over the more commonly prescribed oral medication, Premarin, is that the drug is absorbed directly into the bloodstream without extended metabolism by the digestive system and the liver. Ocular side effects associated with Estraderm, reported in the literature, include fluctuation in corneal curvature and variations of keratitis sicca. Here, a case is presented in which a 50-year-old Caucasian female, without previous ocular sequelae status after hysterectomy and oophorectomy, experienced what appears to be atypical ocular symptoms associated with the Estraderm. To the best of our knowledge, this information has not been reported in the literature. Clinicians should be aware of the unusual symptoms that could accompany the use of the Estradiol Estrogen Replacement Patch and include them among the differential diagnoses. The condition, its associated symptoms, and summary of the literature are discussed.

引用

页码：29 / 33

页数：5

共 15 条

[1]

Ganong W.F., The Gonads: Development and function of the reproductive system, Ganong WF. Review of Medical Physiology, pp. 342-383, (1985)

[2]

Berkow R., Talbott J.H., The Merck Manual of Diagnosis and Therapy, pp. 887-948, (1977)

[3]

Haenggl W., Birkhaeuser M., A new peroral Estrogen/Pro-gestin combination for postmenopausal hormone substitution: An open multicentric study, Maturltas, 16, pp. 111-122, (1993)

[4]

Metka M., Enzelsberger H., Knogler W., Schurz B., Aichmar H., Ophthalmic complaints as a climacteric symptom, Maturitas, 14, pp. 3-8, (1991)

[5]

Disaia P.J., Plormone-replacement therapy in patients with breast cancer: A reappraisal, Cancer, 71, pp. 1490-1500, (1993)

[6]

Smith R.N., Studd J.W., Recent advances in hormone replacement therapy, Br J Plosp Med, 49, pp. 799-808, (1993)

[7]

Jacobs F., Is Amenorrhoea safe? Plormone replacement therapy summary, Lettsomian Lectures, 3, pp. 47-52, (1991)

[8]

Hulka B.S., Kaufman D.G., Fowler W.C., Grlmson R.C., Greenberg B.G., Predominance of early endometrial cancers after long-term Estrogen use, JAMA, 244, pp. 2419-2420, (1990)

[9]

Ml W., Townsend P.T., Pryse-Davies J., Path F., Ryder T.A., King J.B., Effects of Estrogens and Progestins on the biochemistry and morphology of the postmenopausal endometrium, N Engl J Med, 305, pp. 1599-1601, (1981)

[10]

Sturdee D.W., Wade-Evans T., Paterson M., Thom M., Studd J., Relations between bleeding pattern, endometrial histology and oestrogen treatment in menopausal women, Br Med J, 1, pp. 1575-1577, (1978)

← 1 2 →